Serum Institute's large breakthrough in preventing pneumonia, prepared first indigenous vaccine

- Advertisement -

The Serum Institute of India (SII) has developed the first indigenous vaccine. It will be launched next week said Union Health Minister Dr. Harsh Vardhan next week and then soon it will be available in the domestic market next week. According to information from the source, this vaccine will be more affordable. Currently, a vaccine produced by two foreign companies, Pfizer and GlaxoSmithkline, is used for pneumonia.

Also Check: The country’s largest shipping company ready to sell, the government will soon decide on IDBI, BPCL and Air India are also being sold

The Indian drug regulator gave the market approval to the serum institute for the pneumococcal polysaccharide conjugate vaccine in July. The drug regulator took this decision after reviewing the clinical trial data for the first, second and third stages by the institute. This trial was done in India and the African country of Gambia.

The country’s first pneumonia vaccine will be used as an active immunization against pneumonia and invasive diseases (fast-spreading diseases) in children caused by Streptococcus pneumoniae.

Historical achievement amid corona pandemic
In a letter to Union Health Minister Harsh Vardhan, Additional Director (Government and Regulatory Affairs) of Serum Institute, Prakash Kumar Singh, wrote that Prime Minister Narendra Modi’s ambitious plan moving towards self-reliant India, Serum Institute amidst another historic milestone amid Corona pandemic has achieved.

Also Check: How Exercising and Mental Health Help in Stress Management

Annually more than 1 lakh children die at a young age
According to UNICEF data, every year more than one lakh children in India die from pneumococcal diseases at the age of five. Since pneumonia is a respiratory disease, giving PCV to children is very important in the midst of the corona pandemic. Let me tell you that Coronavirus also causes respiratory problems.

- Advertisement -